opucolimab (HLX20) / Fosun Pharma, Shanghai Henlius Biotech - LARVOL DELTA

Preclinical studies reveal that protease-mediated payload release and immuno-oncology/immunomodulatory effects contribute to the antitumor activity of HLX43 (AACR 2026) - "It consists of HLX20, an engineered anti-PD-L1 humanized IgG1 antibody, conjugated via a protease-cleavable tripeptide linker to a potent camptothecin-derived topoisomerase I inhibitor (C24) at a drug-to-antibody ratio (DAR) of 8. Beyond direct cytotoxicity, HLX43 also remodels the TME, with in vivo studies showing increased infiltration of cytotoxic CD8+ T cells and reduced regulatory T cells (Tregs). These CD8+ T cells display enhanced effector function, including elevated IFNγ and Granzyme B expression.In summary, HLX43's convergent mechanisms—combining immune checkpoint inhibition, targeted cytotoxicity, and TME modulation—support its potential as both a monotherapy and in combination with other immuno-oncology agents, positioning HLX43 as a promising therapeutic candidate across diverse tumor types"

Immunomodulating • Immuno-oncology • IO biomarker • Preclinical • Oncology • CALR • CD8 • GZMB • IFNG • IL2

A Phase 1 Study of HLX20, a Human Monoclonal Antibody Targeting PD-L1Protein in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=26 | Completed | Sponsor: Shanghai Henlius Biotech | Recruiting ➔ Completed

Trial completion • Cervical Cancer • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor